Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study finds cognitive behavior therapy more effective than sleeping pills for treating insomnia

28.09.2004


Benefits of non-drug techniques top most popular sleeping pill, Ambien



A study by researchers at Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School has found cognitive behavioral therapy (CBT) is more effective than sleeping pills in treating chronic sleep-onset insomnia. The findings, which appear in the Sept. 27 issue of the Archives of Internal Medicine, show non-drug techniques yield better short and long-term results than the most widely prescribed sleeping pill, zolpidem, commonly known as Ambien. It is the first placebo-controlled trial to evaluate the separate and combined effects of CBT and pharmacological therapies in treating insomnia in young and middle-aged adults.

"Sleeping pills are the most frequent treatment for insomnia, yet, CBT techniques clearly were more successful in helping the majority of study participants to become normal sleepers. The pills were found to be only moderately effective compared to CBT and lost their effectiveness as soon as they were discontinued," said study leader Gregg Jacobs, Ph.D., insomnia specialist in the Sleep Disorders Center of BIDMC and an assistant professor of psychiatry at Harvard Medical School. "Our results suggest CBT should now be considered the first line treatment for insomnia, which is experienced on a nightly basis by one-third of the nation’s adult population," added Jacobs.


Insomnia affects more than 70 million Americans and is one of the most common complaints brought to physician’s offices. Those with the condition experience difficulty initiating or maintaining sleep, often resulting in impaired daytime functioning. In the National Sleep Foundation’s 2002 Sleep in America poll, 35 percent of all adults experienced symptoms every night, with 58 percent reporting insomnia at least a few nights per week.

For the study, researchers conducted a randomized, placebo-controlled clinical trial involving 63 young and middle-aged adults with chronic sleep-onset insomnia. Interventions included behavioral and relaxation techniques, pharmacotherapy (using Ambien), or combined therapy compared with placebo.

Researchers measured sleep twice during an eight week treatment period: at mid-treatment when pharmacotherapy subjects were still taking a nightly does of Ambien and at the end of the eight week treatment period when Ambien subjects gradually tapered their medication and then discontinued it entirely. The main outcome measure was sleep-onset latency as shown by patient diaries. Secondary measures included sleep efficiency and total time as derived from the diaries, objective measures of variables using objective sleep recordings, and an assessment of daytime functioning.

Amongst the findings, CBT and combination groups showed the greatest changes in sleep-onset latency at mid-treatment, both registering a 44 percent reduction. Pharmacotherapy subjects showed a modest 29 percent reduction in latency, followed by 10 percent for the placebo group. At the end of the eight-week treatment period, CBT and combination treatment yielded a 52 percent reduction on sleep-onset latency; these improvements were maintained at long-term follow-up.

The moderate improvements observed in the Ambien group at mid-treatment were not maintained after the drug was gradually tapered and then discontinued. In fact, by the end of the eight-week treatment phase, insomnia returned toward baseline levels and did not differ from the placebo group. CBT and combined therapy also produced the greatest improvements in sleep efficiency and number of normal sleepers by the end of treatment on measures of sleep onset latency and sleep efficiency. There was no advantage of combined therapy over CBT alone. No significant differences emerged amongst groups in total sleep time, though all exhibited increases. The results form the objective sleep recordings paralleled the sleep dairy results.

Despite the fact sleeping pills are the most frequently prescribed treatment for insomnia, and newer generation medications are being introduced to the U.S. market, they are not recommended for long-term treatment. This is due to numerous and well-documented side effects such as dependency. Prior studies also indicate that insomnia patients prefer non-drug approaches.

Study co-authors include Edward Franz Pace-Schott, PhD and Robert Stickgold, PhD, of the BIDMC department of psychiatry; Charles W. Otto, M.D., F.C.C.M, of Massachusetts General Hospital and Harvard Medical School.

This research was funded by grants from the National Institutes of Health.

Marty Querzoli | EurekAlert!
Further information:
http://www.bidmc.harvard.edu

More articles from Studies and Analyses:

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Stiffness matters

22.02.2018 | Life Sciences

Magnetic field traces gas and dust swirling around supermassive black hole

22.02.2018 | Physics and Astronomy

First evidence of surprising ocean warming around Galápagos corals

22.02.2018 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>